Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Review

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Clinical Trial

Comparative Study

Meta-Analysis

Clinical Trial, Phase I

Systematic Review

Comment

Letter

Historical Article

Controlled Clinical Trial

Research Support, N.I.H., Extramural

Multicenter Study

Publication Year

From

Quick links

Individual year

2025

2023

2022

2021

2018

2017

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for

""Catechol O-Methyltransferase Inhibitors""[mesh_terms]

34 Results

Searching titles within these results

Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.

J G Nutt

Neurology 2001;55(11 Suppl 4):S33-7; discussion S38-41

Full Text

Abstract

Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review.

Stefano Zoccolella, Giovanni Iliceto, Michele deMari, Paolo Livrea, Paolo Lamberti

Clinical chemistry and laboratory medicine 2008;45(12):1607-13

Full Text

Abstract

Issues important for rational COMT inhibition.

J Dingemanse

Neurology 2001;55(11 Suppl 4):S24-7; discussion S28-32

Full Text

Abstract

Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.

Tomasz Brzostek, Magdalena Żegleń, Katarzyna Śladowska, Paweł Kawalec

Journal of comparative effectiveness research 2022;11(12):889-904

Free Full Text

Abstract

Prediction of COMT Inhibitors Using Machine Learning and Molecular Dynamics Methods.

Rakesh Kumar Roy, Niladri Patra

The journal of physical chemistry. B 2022;126(19):3477-3492

Full Text

Abstract

Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson's Disease: A Meta-Analysis.

Shaoyue Jin, Jin Hee Kim, Hyeyoon Eo, Myung Sook Oh, Yunsook Lim

Nutrients 2023;15(4):901

Free Full Text

Abstract

Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects.

Johanna Tuunainen, Noora Sjöstedt, Mikko Vahteristo, Juha Ellmén, Mikko Kuoppamäki, Juha Rouru, Marjo Yliperttula

European journal of drug metabolism and pharmacokinetics 2023;48(1):23-34

Full Text

Abstract

Bioactive phytoconstituent millettone as a potential inhibitor of catechol O-methyltransferase: Implications for neuroprotective therapy in Parkinson's disease.

Mohammed H Alqarni, Ahmed I Foudah, Mohammad Khalid

The Journal of pharmacology and experimental therapeutics 2025;392(6):103592

Full Text

Abstract

The Val158Met polymorphism in COMT gene and cancer risk: role of endogenous and exogenous catechols.

Katrin Sak

Drug metabolism reviews 2017;49(1):56-83

Full Text

Abstract

Safinamide in the treatment of Parkinson's disease.

Thomas Müller

Neurodegenerative disease management 2021;10(4):195-204

Full Text

Abstract

Long-term management of Parkinson's disease using levodopa combinations.

Thomas Müller, Jan-Dominique Möhr

Expert opinion on pharmacotherapy 2018;19(9):1003-1011

Full Text

Abstract

Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.

Nuno Borges

Drug safety 2004;26(11):743-7

Full Text

Abstract

Levodopa: past, present, and future.

Robert A Hauser

European neurology 2009;62(1):1-8

Full Text

Abstract

Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.

P Livrea, S Zoccolella, P Lamberti, E Armenise, M de Mari, S V Lamberti, R Mastronardi, A Fraddosio, G Iliceto

Parkinsonism & related disorders 2005;11(2):131-3

Full Text

Abstract

The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.

Theresa A Zesiewicz, Lynn Wecker, Kelly L Sullivan, Lisa R Merlin, Robert A Hauser

Clinical neuropharmacology 2006;29(3):106-11

Full Text

Abstract

Results: 1 – 15 / 34

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Catechol O-Methyltransferase Inhibitors""[mesh_terms]

Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.

Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review.

Issues important for rational COMT inhibition.

Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.

Prediction of COMT Inhibitors Using Machine Learning and Molecular Dynamics Methods.

Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson's Disease: A Meta-Analysis.

Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects.

Bioactive phytoconstituent millettone as a potential inhibitor of catechol O-methyltransferase: Implications for neuroprotective therapy in Parkinson's disease.

The Val158Met polymorphism in COMT gene and cancer risk: role of endogenous and exogenous catechols.

Safinamide in the treatment of Parkinson's disease.

Long-term management of Parkinson's disease using levodopa combinations.

Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.

Levodopa: past, present, and future.

Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.

The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.

Results for

""Catechol O-Methyltransferase Inhibitors""[mesh_terms]